Efficacy of cascade-primed cell infusion as an adjuvant immunotherapy with concurrent chemotherapy for patients with non–small-cell lung cancer: A retrospective observational study with a 5-year follow-up
ConclusionCAPRI cell therapy potentially prolongs the survival of patients with NSCLC when combined with chemotherapy.
Source: Cytotherapy - Category: Cytology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Cytology | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Study | Toxicology